The upcoming session addresses the critical friction points in modern oncology research, where matching therapies to individual molecular profiles remains complex. Speakers from Thermo Fisher Scientific’s PPD clinical research business and Clario will detail methods for leveraging high-quality real-world evidence alongside linked clinical and genomic datasets. These digital tools serve to accelerate evidence generation, which is increasingly vital for securing regulatory approval and reimbursement in a competitive landscape.

Participants will gain insight into the practical application of decentralized and hybrid trial models designed to widen the reach for biomarker-eligible patients. The panel features Dr. Mark Yates, Dr. Jai Balkissoon, Ethel Pilati, Dr. Anu Bansal, Jane Li, and Yarden Ginsburg, who will collectively demonstrate how bridging the gap between genomic data and clinical endpoint analysis can foster broader adoption of targeted therapies. The event is scheduled for 11:00 AM EDT, providing a technical look at the tools currently shaping the next generation of precision medicine.